The Experts below are selected from a list of 17109 Experts worldwide ranked by ideXlab platform
Deepak L Bhatt - One of the best experts on this subject based on the ideXlab platform.
-
stent only versus adjunctive balloon angioplasty approach for Saphenous Vein Graft percutaneous coronary intervention insights from diva trial
Circulation-cardiovascular Interventions, 2020Co-Authors: Faisal Latif, Deepak L Bhatt, Lauren Uyeda, Robert Edson, David R Holmes, Sunil V Rao, Steven Goldman, Kendrick A ShunkAbstract:Background: Direct stenting without pre-dilation or post-dilation has been advocated for Saphenous Vein Graft percutaneous coronary intervention to decrease the incidence of distal embolization, pe...
-
drug eluting stents versus bare metal stents in Saphenous Vein Graft intervention
Circulation-cardiovascular Interventions, 2018Co-Authors: Nileshkumar Patel, George Dangas, Chirag Bavishi, Varunsiri Atti, Avnish Tripathi, Nikhil Nalluri, Mauricio G Cohen, Annapoorna Kini, Samin K Sharma, Deepak L BhattAbstract:Background Percutaneous coronary intervention with drug-eluting stents (DES) has been increasingly used for revascularization of Saphenous Vein Graft stenosis without strong clinical evidence favor...
-
drug eluting stents versus bare metal stents in Saphenous Vein Graft intervention
Circulation-cardiovascular Interventions, 2018Co-Authors: Nileshkumar J Patel, George Dangas, Chirag Bavishi, Varunsiri Atti, Avnish Tripathi, Nikhil Nalluri, Mauricio G Cohen, Annapoorna Kini, Samin K Sharma, Deepak L BhattAbstract:Background Percutaneous coronary intervention with drug-eluting stents (DES) has been increasingly used for revascularization of Saphenous Vein Graft stenosis without strong clinical evidence favoring their use. Randomized controlled trials comparing DES versus bare-metal stents (BMS) in Saphenous Vein Graft-percutaneous coronary intervention have been inconclusive. Methods and Results We performed a comprehensive literature search through May 15, 2018, for all eligible studies comparing DES versus BMS in patients with Saphenous Vein Graft stenosis in PubMed, EMBASE, SCOPUS, Google Scholar, and ClinicalTrials.gov. Clinical outcomes included all-cause mortality, cardiovascular mortality, major adverse cardiovascular events, myocardial infarction, stent thrombosis, and target vessel revascularization. Six randomized controlled trials were eligible and included 1582 patients, of whom 797 received DES and 785 received BMS. The follow-up period ranged from 18 months to 60 months. There was no statistically significant difference between DES and BMS for all-cause mortality (risk ratio [RR],1.11; 95% CI, 0.0.77-1.62; P=0.57), cardiovascular mortality (RR, 1.00; 95% CI, 0.64-1.57; P=0.99), major adverse cardiovascular events (RR, 0.83; 95% CI, 0.63-1.10; P=20), target vessel revascularization (RR, 0.73; 95% CI, 0.48-1.11; P=0.14), myocardial infarction (RR, 0.74; 95% CI, 0.48-1.16; P=0.19), or stent thrombosis (RR, 1.06; 95% CI, 0.42-2.65; P=0.90). Conclusions In patients undergoing percutaneous coronary intervention for Saphenous Vein Graft lesions, our results showed that there was no significant difference between DES and BMS for mortality, major adverse cardiovascular events, target vessel revascularization, myocardial infarction, or stent thrombosis.
David R Holmes - One of the best experts on this subject based on the ideXlab platform.
-
stent only versus adjunctive balloon angioplasty approach for Saphenous Vein Graft percutaneous coronary intervention insights from diva trial
Circulation-cardiovascular Interventions, 2020Co-Authors: Faisal Latif, Deepak L Bhatt, Lauren Uyeda, Robert Edson, David R Holmes, Sunil V Rao, Steven Goldman, Kendrick A ShunkAbstract:Background: Direct stenting without pre-dilation or post-dilation has been advocated for Saphenous Vein Graft percutaneous coronary intervention to decrease the incidence of distal embolization, pe...
-
tct 675 direct stenting versus adjunctive balloon angioplasty for Saphenous Vein Graft percutaneous coronary intervention
Journal of the American College of Cardiology, 2019Co-Authors: Faisal Latif, Barry F. Uretsky, Lauren Uyeda, Robert Edson, David R Holmes, Sunil V Rao, Kul Aggarwal, Khaled M Ziada, Edward O Mcfalls, Anand IrimpenAbstract:Direct stenting without pre- or post-dilation has been advocated for Saphenous Vein Graft (SVG) percutaneous coronary intervention (PCI) to decrease the incidence of periprocedural myocardial infarction (MI) and target lesion revascularization (TLR). In an analysis of the DIVA (Drug-Eluting Stents
-
predictors and sequelae of distal embolization during Saphenous Vein Graft intervention from the caveat ii trial
Circulation, 1995Co-Authors: Jeffrey Lefkovits, Robert D Safian, David R Holmes, Robert M Califf, Karen S Pieper, Gordon Keeler, Eric J. TopolAbstract:Background The purpose of this study was to identify the predictors and sequelae of distal embolization from a multicenter, randomized trial of Saphenous Vein Graft intervention. The CAVEAT-II trial demonstrated that Saphenous Vein Graft directional coronary atherectomy (DCA) was associated with greater angiographic success and less need for repeat intervention compared with percutaneous transluminal coronary angioplasty (PTCA) but at the cost of more acute complications—notably distal embolization. Methods and Results In CAVEAT-II, 305 patients were randomly assigned to DCA (149 patients) or PTCA (156 patients) for lesions with >60% diameter stenosis in Vein Grafts ≥3 mm in diameter. Distal embolization occurred in 20 patients (13.4%) assigned to DCA and 8 patients (5.1%) assigned to PTCA (P=.011). Independent predictors of distal embolization were use of DCA (71% in distal embolization patients versus 47% in patients without distal embolization, P=.011) and presence of thrombus (39% in distal embolizati...
Faisal Latif - One of the best experts on this subject based on the ideXlab platform.
-
stent only versus adjunctive balloon angioplasty approach for Saphenous Vein Graft percutaneous coronary intervention insights from diva trial
Circulation-cardiovascular Interventions, 2020Co-Authors: Faisal Latif, Deepak L Bhatt, Lauren Uyeda, Robert Edson, David R Holmes, Sunil V Rao, Steven Goldman, Kendrick A ShunkAbstract:Background: Direct stenting without pre-dilation or post-dilation has been advocated for Saphenous Vein Graft percutaneous coronary intervention to decrease the incidence of distal embolization, pe...
-
tct 675 direct stenting versus adjunctive balloon angioplasty for Saphenous Vein Graft percutaneous coronary intervention
Journal of the American College of Cardiology, 2019Co-Authors: Faisal Latif, Barry F. Uretsky, Lauren Uyeda, Robert Edson, David R Holmes, Sunil V Rao, Kul Aggarwal, Khaled M Ziada, Edward O Mcfalls, Anand IrimpenAbstract:Direct stenting without pre- or post-dilation has been advocated for Saphenous Vein Graft (SVG) percutaneous coronary intervention (PCI) to decrease the incidence of periprocedural myocardial infarction (MI) and target lesion revascularization (TLR). In an analysis of the DIVA (Drug-Eluting Stents
George Dangas - One of the best experts on this subject based on the ideXlab platform.
-
drug eluting stents versus bare metal stents in Saphenous Vein Graft intervention
Circulation-cardiovascular Interventions, 2018Co-Authors: Nileshkumar Patel, George Dangas, Chirag Bavishi, Varunsiri Atti, Avnish Tripathi, Nikhil Nalluri, Mauricio G Cohen, Annapoorna Kini, Samin K Sharma, Deepak L BhattAbstract:Background Percutaneous coronary intervention with drug-eluting stents (DES) has been increasingly used for revascularization of Saphenous Vein Graft stenosis without strong clinical evidence favor...
-
drug eluting stents versus bare metal stents in Saphenous Vein Graft intervention
Circulation-cardiovascular Interventions, 2018Co-Authors: Nileshkumar J Patel, George Dangas, Chirag Bavishi, Varunsiri Atti, Avnish Tripathi, Nikhil Nalluri, Mauricio G Cohen, Annapoorna Kini, Samin K Sharma, Deepak L BhattAbstract:Background Percutaneous coronary intervention with drug-eluting stents (DES) has been increasingly used for revascularization of Saphenous Vein Graft stenosis without strong clinical evidence favoring their use. Randomized controlled trials comparing DES versus bare-metal stents (BMS) in Saphenous Vein Graft-percutaneous coronary intervention have been inconclusive. Methods and Results We performed a comprehensive literature search through May 15, 2018, for all eligible studies comparing DES versus BMS in patients with Saphenous Vein Graft stenosis in PubMed, EMBASE, SCOPUS, Google Scholar, and ClinicalTrials.gov. Clinical outcomes included all-cause mortality, cardiovascular mortality, major adverse cardiovascular events, myocardial infarction, stent thrombosis, and target vessel revascularization. Six randomized controlled trials were eligible and included 1582 patients, of whom 797 received DES and 785 received BMS. The follow-up period ranged from 18 months to 60 months. There was no statistically significant difference between DES and BMS for all-cause mortality (risk ratio [RR],1.11; 95% CI, 0.0.77-1.62; P=0.57), cardiovascular mortality (RR, 1.00; 95% CI, 0.64-1.57; P=0.99), major adverse cardiovascular events (RR, 0.83; 95% CI, 0.63-1.10; P=20), target vessel revascularization (RR, 0.73; 95% CI, 0.48-1.11; P=0.14), myocardial infarction (RR, 0.74; 95% CI, 0.48-1.16; P=0.19), or stent thrombosis (RR, 1.06; 95% CI, 0.42-2.65; P=0.90). Conclusions In patients undergoing percutaneous coronary intervention for Saphenous Vein Graft lesions, our results showed that there was no significant difference between DES and BMS for mortality, major adverse cardiovascular events, target vessel revascularization, myocardial infarction, or stent thrombosis.
-
Comparison of time course of target lesion revascularization following successful Saphenous Vein Graft angioplasty versus successful native coronary angioplasty.
The American journal of cardiology, 2000Co-Authors: Mun K. Hong, Gary S. Mintz, Augusto D. Pichard, Kenneth M. Kent, Lowell F. Satler, Roxana Mehran, George Dangas, Alexandra J. Lansky, Gregg W. Stone, Martin B. LeonAbstract:We studied 1,267 patients with 2,186 Saphenous Vein Graft (SVG) lesions to determine the time course of target lesion revascularization (TLR) after successful SVG angioplasty. We found that the time course of TLR in SVG appears prolonged, with only 54% occurring within the first 6 months and continued TLR even after 1 year.
Kendrick A Shunk - One of the best experts on this subject based on the ideXlab platform.
-
stent only versus adjunctive balloon angioplasty approach for Saphenous Vein Graft percutaneous coronary intervention insights from diva trial
Circulation-cardiovascular Interventions, 2020Co-Authors: Faisal Latif, Deepak L Bhatt, Lauren Uyeda, Robert Edson, David R Holmes, Sunil V Rao, Steven Goldman, Kendrick A ShunkAbstract:Background: Direct stenting without pre-dilation or post-dilation has been advocated for Saphenous Vein Graft percutaneous coronary intervention to decrease the incidence of distal embolization, pe...
